A retrospective study to evaluate association between Neutrophil to lymphocyte ratio (NLR) kinetics as predictors of treatment outcomes in patients with renal cell carcinoma and non-small cell lung cancer treated with nivolumab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer; Renal cell carcinoma
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

01 Dec 2020 Results exploring the association between Best Overall Response (BOR) and NLR variations in mRCC pts, published in the Cancer Immunology Immunotherapy
14 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight